This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

R. L. KENDRICK, M.D.; KENT BALLS, M.D.; EDWARD ROSE, M.D.

AMA Arch Intern Med. 1952;89(3):368-373.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

THIS report deals with the use of 1-methyl-2-mercaptoimidazole in the treatment of thyrotoxicosis. Figure 1 shows its structural formula, and, with it, that of 6-n-propylthiouracil. There were 32 selected thyrotoxic patients in our series. Fifteen had been previously treated with iodine or a thiouracil; all except two, however, had completely relapsed on cessation of previous therapy. In both exceptions partial remission had been induced with methylthiouracil treatment. None represented examples of recurrent postoperative thyrotoxicosis.

CLINICAL MATERIAL

Our patients fall into two groups. In 17 treatment was begun with the hope of inducing a prolonged or permanent remission without operation. In 15 treatment was preoperative. Data on these groups are shown in the Table. In the first group the patients' ages ranged from 5 to 54 years. Three were children, aged 5, 5, and 8 years. Fourteen were females, and three males. Sixteen had diffuse goiters and one no palpable goiter. . . . [Full Text PDF of this Article]

Author Affiliations
ROCHESTER, MINN.; PHILADELPHIA

From the Endocrine Section. Medical Clinic, Hospital of the University of Pennsylvania.

Footnotes
Dr. Kendrick is from the Division of Medicine, Mayo Clinic.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?